Reschedule of Boar Meeting and Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parmax Pharma reported deeply negative FY26 results, with revenue from operations falling sharply to about Rs 12.11 crore from Rs 28.20 crore in FY25, a roughly 57% year-on-year drop. Net loss nearly doubled to Rs 4.16 crore versus Rs 2.09 crore last year, while Q4 FY26 revenue dropped to Rs 3.31 crore from Rs 4.83 crore in Q4 FY25. The company's balance sheet shows negative total equity of Rs (6.15) crore, with non-current borrowings rising to Rs 11.52 crore from Rs 7.70 crore, and cash flow from operations was negative at Rs (2.36) crore. The auditor flagged several key audit matters including a pending Rs 3.5 crore fire-related insurance claim, non-provision of depreciation on clean room and effluent treatment plants, employee benefits accounted on cash basis instead of accrual basis, and acceptance of Rs 61.17 lakh deposits from an LLP that contravenes RBI directives. Despite these matters, the auditor issued an unmodified opinion and the MD declared the same.
Shareholders face a worsening financial position with negative net worth, mounting borrowings, persistent losses, and negative operating cash flow, raising serious going-concern doubts despite the clean audit opinion. The sharp revenue decline, unresolved insurance claim from the 2023 fire, and multiple regulatory non-compliances flagged by auditors are significant red flags for the stock.